Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates
27 juil. 2022 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics...
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
24 juin 2022 07h30 HE
|
Intellia Therapeutics, Inc.
Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and...
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022
08 juin 2022 07h30 HE
|
Intellia Therapeutics, Inc.
Oral presentation to include additional durability data from patients treated with NTLA-2001, the first-ever systemically administered in vivo CRISPR investigational therapyPresentation to include...
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
05 mai 2022 07h30 HE
|
Intellia Therapeutics, Inc.
Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single dose of NTLA-2001 resulted in rapid, deep and...
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
02 mai 2022 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging...
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference
02 mai 2022 07h30 HE
|
Intellia Therapeutics, Inc.
Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell therapyFindings support recent development candidate...
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates
28 avr. 2022 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
09 mars 2022 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia
01 mars 2022 07h30 HE
|
Intellia Therapeutics, Inc.
NTLA-5001 is a novel investigational T cell receptor (TCR)-T cell therapy which leverages Intellia’s proprietary cell engineering platform NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed...
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
28 févr. 2022 16h01 HE
|
Intellia Therapeutics, Inc.
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsDurable serum TTR reductions...